The North America Anatomic Pathology Market size was valued at USD 4,350 Million in 2025 and is expected to reach USD 7,950 Million by 2035, expanding at a CAGR of 5.7% from 2024 to 2035. The market is driven by increasing prevalence of cancer and chronic diseases, technological advancements, and growing adoption of digital pathology solutions.
The economic impact of tariffs on "North America Anatomic Pathology Market".
Market Growth Drivers
1. Rising Incidence of Cancer and Chronic Diseases: The increasing prevalence of cancer, which according to the American Cancer Society, affects over 2 million new patients annually in North America, is a primary driver for the demand for anatomic pathology. Companies like Thermo Fisher Scientific are investing in advanced pathology solutions to enhance cancer diagnostics, enabling faster and more accurate detection and personalized care.
2. Technological Advancements and Digital Transformation: The integration of Artificial Intelligence (AI), cloud computing, and digital imaging technologies has transformed traditional pathology workflows. Roche Diagnostics has pioneered digital pathology platforms, allowing remote access, image analysis, and improved collaboration among pathologists, thus reducing turnaround times and boosting diagnostic accuracy.
Market Trends
1. Growing Adoption of Digital Pathology: The shift towards digital pathology platforms, such as those offered by Philips and Leica Biosystems, is significantly altering the diagnostic landscape. These solutions facilitate telepathology, automated scanning, and image analysis, resulting in enhanced workflow efficiency and lower operational costs. The COVID-19 pandemic further accelerated digital adoption due to the necessity for remote diagnostics.
2. Expansion of Companion Diagnostics: There is an increasing trend of integrating companion diagnostics into anatomic pathology practices. Companies like Agilent Technologies are developing pathologist-driven diagnostics that allow for targeted therapies in oncology, enhancing treatment outcomes, and supporting the rise of precision medicine in the North American market.
Market Opportunities
1. Untapped Potential in Community Hospitals and Ambulatory Centers: Many smaller hospitals and ambulatory centers in rural or underserved regions have yet to fully integrate advanced anatomic pathology technology. Advanced solutions from players like Sakura Finetek and Danaher Corporation present growth opportunities through market penetration and service expansion.
2. Integration of AI-Powered Predictive Analytics: The use of artificial intelligence in predictive diagnostics holds strong promise. Companies such as Paige.AI are developing algorithms that provide earlier disease detection and stratification, presenting a major opportunity for market differentiation and improved patient outcomes.
North America Anatomic Pathology Market Revenue (USD Million), 2020-2035
The market revenue for North America Anatomic Pathology has consistently increased from 2020 to 2035. Beginning at USD 2,800 million in 2020, the market demonstrates robust year-on-year growth fueled by rising disease incidence, expansion of healthcare infrastructure, and technology adoption. By 2025, the revenue reaches USD 4,350 million, with projections estimating continued strong growth to USD 7,950 million by 2035. The market's healthy CAGR of 5.7% underscores the rising dependence on pathology for diagnostic accuracy and personalized medicine across the region.
North America Anatomic Pathology Market by Regions Share (%), 2025
In 2025, the United States dominates the North America Anatomic Pathology Market, accounting for 79% of the market share due to advanced healthcare infrastructure and robust adoption of innovative technologies. Canada holds 17% driven by increasing investment in disease diagnostics, while Mexico covers 3%, reflecting developing healthcare systems. Other North American territories collectively comprise 1%. The trend highlights the disproportionate concentration in the U.S., with Canada and Mexico showing growing potential as digital transformation and healthcare funding increase.
Recent Developments in North America Anatomic Pathology Market (Last 6 Months)
1. In March 2024, Roche Diagnostics received FDA clearance for its new digital slide scanner, enhancing remote workflow capabilities for pathologists and institutions across North America. This product is expected to bolster digital uptake and facilitate faster, more secure diagnostic services.
2. In April 2024, Paige.AI partnered with LabCorp to deploy AI-powered pathology image analysis at select LabCorp facilities in the United States. This collaboration aims to combine Paige's machine learning expertise with LabCorp's extensive laboratory network to elevate the accuracy and efficiency of cancer diagnostics.
3. In May 2024, Leica Biosystems launched an advanced multiplex immunohistochemistry (IHC) platform designed for simultaneous analysis of multiple biomarkers. This platform enhances complex cancer tissue analysis and supports comprehensive clinical decision-making, reinforcing Leica's competitive stance in the North American market.
Press Releases